ConductScience.org, home

Paper3207553

Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.

Riley SA and 3 others. Br J Clin Pharmacol, 1988. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Papers, record 3207553. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3207553

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
1988
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
1.66
iCite
Revised in PubMed
2019-05-10
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Riley SAS A
2Tavares IAI A
3Bennett AA
4Mani VV

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aminosalicylic AcidsMajor topic
IleostomyMajor topic
Adult
Chemistry, Pharmaceutical
Delayed-Action Preparations
Female
Humans
Hydrogen-Ion Concentration
Male
Mesalamine
Middle Aged
Solubility

Source PubMed

Download CSV of topics

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15937767Ionic constituents and osmolality of gastric and small-intestinal fluids after eating.Am J Dig Dis1966https://conductscience.org/library/papers/5937767PubMed
24146729Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.N Engl J Med1973https://conductscience.org/library/papers/4146729PubMed
34448417Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device.Gut1974https://conductscience.org/library/papers/4448417PubMed
472239An experiment to determine the active therapeutic moiety of sulphasalazine.Lancet1977https://conductscience.org/library/papers/72239PubMed
536326Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.Gastroenterology1979https://conductscience.org/library/papers/36326PubMed
636332Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).Gut1979https://conductscience.org/library/papers/36332PubMed
714238045PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.Lancet1965https://conductscience.org/library/papers/14238045PubMed
87126413An oral preparation to release drugs in the human colon.Br J Clin Pharmacol1982https://conductscience.org/library/papers/7126413PubMed
96615691Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6615691PubMed
106661362Kinetics of 5-aminosalicylic acid after jejunal instillation in man.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6661362PubMed
116675167Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.Scand J Gastroenterol1983https://conductscience.org/library/papers/6675167PubMed
123979912Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.Gut1985https://conductscience.org/library/papers/3979912PubMed
1313865153Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.Lancet1962https://conductscience.org/library/papers/13865153PubMed
146127096Azo reduction of sulphasalazine in healthy volunteers.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6127096PubMed

Download CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
26883035Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.Drugs R D2016https://conductscience.org/library/papers/26883035PubMed
25478568Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration.Biomed Res Int2014https://conductscience.org/library/papers/25478568PubMed
20049950Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.Inflamm Bowel Dis2010https://conductscience.org/library/papers/20049950PubMed
20049949Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.Inflamm Bowel Dis2010https://conductscience.org/library/papers/20049949PubMed
18484800Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.Drugs2008https://conductscience.org/library/papers/18484800PubMed
11247905Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.Gut2001https://conductscience.org/library/papers/11247905PubMed
9723828Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.Br J Clin Pharmacol1998https://conductscience.org/library/papers/9723828PubMed
8504969Oroileal transit of slow release 5-aminosalicylic acid.Gut1993https://conductscience.org/library/papers/8504969PubMed
2684592Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs1989https://conductscience.org/library/papers/2684592PubMed
2199130Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).Clin Pharmacokinet1990https://conductscience.org/library/papers/2199130PubMed
1550697Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).Br J Clin Pharmacol1992https://conductscience.org/library/papers/1550697PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3207553

GET https://conductscience.org/api/papers/v1/3207553/authors